Spots Global Cancer Trial Database for pamiparib
Every month we try and update this database with for pamiparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | NCT05376722 | Neoadjuvant The... | pamiparib abiraterone prednisone | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | NCT04796454 | Platinum-Sensit... | Cisplatin Gemcitabine Oxaliplatin Pamiparib Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma | NCT03150862 | Brain and Centr... | Pamiparib TMZ Radiation | 18 Years - | BeiGene | |
| A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | NCT05489926 | Epithelial Ovar... | Pamiparib | 18 Years - | Zhejiang Cancer Hospital | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Study of Pamiparib in Newly Diagnosed and rGBM | NCT04614909 | Glioblastoma Glioblastoma Mu... Glioblastoma Mu... | Pamiparib Olaparib Radiation thera... Temozolomide | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| PPK Study Based on Quantitative Pharmacology in Patients With Pamipril | NCT05848648 | Ovarian Cancer | 18 Years - 80 Years | Qianfoshan Hospital | ||
| Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors | NCT03333915 | Advanced High-g... Triple Negative... | Pamiparib | 18 Years - | BeiGene | |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | NCT03712930 | Metastatic Cast... Homologous Reco... | Pamiparib | 18 Years - | BeiGene | |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | NCT05494580 | Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton... | Pamiparib Surufatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | NCT05652283 | Ovarian Cancer | Pamiparib Surufatinib | 18 Years - | Anhui Provincial Cancer Hospital | |
| Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | NCT05483543 | Limited Stage S... | Pamiparib | 18 Years - | Fudan University | |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | NCT04603365 | Clear Cell Papi... Collecting Duct... Hereditary Leio... Hereditary Papi... Metastatic Rena... Metastatic Uncl... Papillary Renal... Stage III Renal... Stage IV Renal ... Tubulocystic Re... Unresectable Re... | Pamiparib Temozolomide | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | NCT04985721 | Cancer | Pamiparib Tislelizumab | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | NCT05376722 | Neoadjuvant The... | pamiparib abiraterone prednisone | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | NCT03712930 | Metastatic Cast... Homologous Reco... | Pamiparib | 18 Years - | BeiGene | |
| Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | NCT03994211 | Solid Tumor | pamiparib 60 mg pamiparib 20 mg itraconazole rifampin pamiparib | 18 Years - | BeiGene | |
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) | NCT06387056 | Locally Advance... Oligometastatic... | Rezvilutamide Goserelin Micro... Docetaxel Pamiparib Cisplatin Tislelizumab | 18 Years - | The First Affiliated Hospital of Xiamen University | |
| Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | NCT04796454 | Platinum-Sensit... | Cisplatin Gemcitabine Oxaliplatin Pamiparib Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
